Anavex Life Sciences presented new findings that link autism spectrum disorder and Alzheimer’s disease through impaired autophagy and related synaptic dysfunction, and the company frames these observations as a rationale for its autophagy-targeting oral therapy, Blarcamesine.
According to the company, multiple peer-reviewed studies and converging human genetic evidence implicate high-confidence ASD risk genes, including TSC1/TSC2, PTEN, SHANK3 and FMRP, in autophagy dysfunction and failed synaptic pruning.
The company highlights epidemiological analyses indicating autistic adults may be diagnosed with dementia at rates up to eight times higher than the general population and notes extracellular matrix alterations that interact with autophagy pathways.
Anavex cites preclinical data showing that Blarcamesine restores autophagy via SIGMAR1 activation, and references clinical signals spanning Phase IIb/III Alzheimer’s studies, Phase II/III Rett syndrome trials, and Phase II Parkinson’s disease dementia work as supporting cross-lifespan development. The company claims these data provide a scientific basis to advance Blarcamesine into pivotal clinical studies, subject to further evaluation and regulatory considerations.
